DOTTER is a globally patented technology-based healthcare company that provides solutions for diagnosing and treating lesions that cause ischemic heart disease.
As a company established by a combination of cardiovascular specialists and the best experts in Korea and the world in the field of optical coherence tomography (OCT), we are designing and producing sophisticated biodegradable stents (BRS) that are 1/3 the thickness of competitors. In addition, we are mainly developing next-generation OCT equipment, which is optical imaging equipment that can create a synergistic effect for stent insertion.
We aspire to diagnose and cure cardiovascular disease, the leading cause of mortality worldwide, using our unrivaled technological competitiveness, so that humankind can escape the pain of cardiovascular disease and enjoy a longer, healthier life.
Even now, while we pursue continuous technological innovation, we are focusing all our efforts and passion on ensuring the satisfaction of our customers and patients by prioritizing quality and safety.
Subscribe to our media mailing list and get updated with our most recent news
[Ulsan=Newsis] Reporter Hyun-cheol Cho = Ulsan Hospital announced on January 27 that it had performed the first coronary intervention in the country to insert a more improved absorbable stent for a 50-year-old male angina patient at the Cardiocerebrovascular Center on January 20.
The Korea Health Industry Development Institute (President Deok-cheol Kwon), along with the domestic venture investment platform KDB NextRound, held the ‘2019 5th K-BIC STAR DAY’ (hereafter K-BIC Star Day) held at the IR Center of the KDB in Yeouido on the 1st. It was announced on the 2nd that it was successfully held.
info@dotter.com
